New Phase II data show evobrutinib sustained low annualized relapse rates (ARRs) and had no new safety signals at 2.5 years the longest follow-up of any Bruton's tyrosine kinase inhibitor in multiple
Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022 - Iberonews iberonews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iberonews.com Daily Mail and Mail on Sunday newspapers.